瑞士科學期刊研究報告：高端疫苗「保護力84%」 科興、國藥僅65% - 新頭殼

6/22/2022 12:00:00 AM2 years 10 months ago
by 新頭殼 newtalk

國產高端疫苗受世界衛生組織（WHO）支持的新冠疫苗全球三期臨床試驗已進入資料分析，而近期瑞士科學期刊MDPI（Multidisciplinary Digital Publishing Institute）刊出一份題為《對 SARS-CoV-2 疫苗的免疫反應》（Immune Response to

WHOMDPIMultidisciplinary Digital Publishing Institute SARS-CoV-2 Immune Response to SARSCoV2 VaccinesMVC COVID19 vaccine84% 84%Overall efficacy: 84%No vaccinerelated Serious Adverse ReactionBNT95%94… [+367 chars]

full article...